SCHEMBL7067338

SCHEMBL7067338

C=CCOc1ccc(C=O)cc1Cc1c(OCC=C)ccc(C=O)c1-c1ccc(O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.39
MGAM O43451 4/20 0.39
SI P14410 4/20 0.39
MGAM2 Q2M2H8 4/20 0.39
ALDH2 P05091 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
ERN1 O75460 1/20 0.34
ALDH1A1 P00352 6/20 0.34
CYP1A2 P05177 1/20 0.33
MAPK1 P28482 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.32
HPGD P15428 2/20 0.31
MEN1 O00255 1/20 0.31
POLB P06746 1/20 0.31
KMT2A Q03164 1/20 0.31
ALDH5A1 P51649 1/20 0.31
ABAT P80404 1/20 0.31
AOX1 Q06278 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7071776 0.85 ERN1 (0.42) GAAMGAMSIMGAM2ERN1
SCHEMBL7073794 0.76 MAOA (0.48) MAOAMAOBERN1ALDH1A1
SCHEMBL7072179 0.76 KDM4E (0.39) ERN1ALDH1A1KDM4EHPGDALDH5A1
SCHEMBL7069599 0.72 CYP1A2 (0.44) ERN1ALDH1A1CYP1A2TSHRHPGD
SCHEMBL19251015 0.71 MAOA (0.46) GAAMAOAMAOBALDH1A1TSHR
SCHEMBL6771880 0.71 ALDH1A1 (0.43) GAAALDH1A1CYP1A2MAPK1KDM4E
SCHEMBL8534293 0.71 KDM4E (0.48) GAAALDH1A1CYP1A2MAPK1KDM4E
SCHEMBL1923931 0.70 ALDH1A1 (0.46) GAAALDH1A1MAPK1KDM4ETSHR
SCHEMBL1422917 0.69 ALDH1A1 (0.57) GAAALDH1A1MAPK1KDM4ETSHR
SCHEMBL3954852 0.69 GAA (0.41) GAAMGAMSIMGAM2ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092685-A1 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases NITZ THEODORE J (US) 2003-05-15 US disclosed
EP-1051169-A4 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES VIROPHARMA INC (US) 2002-05-29 EP disclosed
EP-1051169-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES Viropharma Incorporated (US) 2000-11-15 EP disclosed
WO-1999038508-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES VIROPHARMA INCORPORATED (US) 1999-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092685-A1 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases TTPA, HAVCR2, PML GAA 1534/4885MGAM 664/4885SI 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.